Answers are grounded in this paper and cite their sources.
We studied the impact of zidovudine (AZT) in Cas-Br-M murine leukemia virus-infected NFS-N mice after administration by once-daily bolus or continuous infusion. While higher peak concentrations of AZT were achieved by once-daily dosing, continuous AZT infusion at 25 micrograms/h maintained levels > 1 microM in plasma and > 0.2 microM in the brain. Continuous infusion provided significantly better viral inhibition, even though total doses were only one-third that of the once-daily therapy group.
No takes yet. Share an insight, caveat, or question.
Bilello et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: